chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: M
Vaccine: MMR, VARCEL
Symptoms: Inappropriate schedule of product administration, No adverse event
Clinical narrative: No additional AE reported.; Physician was reviewing old records and noticed that back in 2007, patient was administered MMR and VARIVAX too close together.; This spontaneous report was received from an registered nurse and refers to a male patient of unknown age.  The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 07-JUN-2007, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) injection, administered for prophylaxis (strength, lot #, expiry date, and route of administration were not provided). On 19-JUN-2007, the patient was vaccinated with varicella virus vaccine live (oka/merck) (VARIVAX) injection, administered for prophylaxis (strength, lot #, expiry date, and route of administration were not provided).  Physician was reviewing old records and noticed that back in 2007, patient was administered measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) and varicella virus vaccine live (oka/merck) (VARIVAX) too close together (Inappropriate schedule of product administration). This agent attempted to probe to inquire if nurse was referring to measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II), but nurse stated all that was documented is that is was Merck's measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) vaccine. No further information provided. No additional adverse event was reported.
Sex: U
Vaccine: VARCEL
Symptoms: Expired product administered, No adverse event
Clinical narrative: No AE/PQC reported; VARIVAX accidentally administered to a patient /; This spontaneous report has been received from a healthcare professional concerning a patient of unknown age and gender. Their concurrent conditions, medical history, drug reactions/allergies, and concomitant medications were not provided.   On 30-MAY-2023, the patient was vaccinated accidentally with one expired dose of varicella virus vaccine live (Oka/Merck) (VARIVAX) administered as prophylaxis, lot number U015686 with expiration date 18-MAY-2023 (dosage regimen and route of administration was not provided) (Expired product administered). No adverse event reported (No adverse event).
Age: 91.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: COVID-19 Treatment; COVID-19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 92-year-old female patient received BNT162b2 (BNT162B2), on 30Jan2021 as dose 1, single (Lot number: EL9264), on 20Feb2021 as dose 2, single (Lot number: EN6198) and on 13Jan2022 as dose 3 (booster), single (Lot number: FJ1614) at the age of 91 years for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: hepatitis B, administration date: 06May1930, for Hepatitis B immunization; dtap/dt/td, administration date: 06May1949, for Immunisation; herpes zoster, administration date: 06May1949, for Immunisation; dtap/dt/td, administration date: 06May1980, for Immunisation; pneumo (pcv), administration date: 06May1995, for Immunisation. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID-19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: patient received PAXLOVID treatment.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300157702 same reporter/patient, different drug/event;
Age: 6.0
Sex: M
Vaccine: IPV
Symptoms: Medication error, No adverse event, Poor quality product administered, Product storage error
Clinical narrative: Temperature excursion for opened IPOL was administered to patient with no adverse event; Initial information received on 25-May-2023 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 6 years old male patient who had administered temperature excursion for opened ipol with no adverse event while receiving vaccine IPV (VERO) [IPOL].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 05-Jan-2023, the patient received 0.5 ml of suspect IPV (VERO) Suspension for injection lot V1A121M, 15-FEB-2024 via intramuscular route in the left arm for Immunization.  On 05-Jan-2023 the patient developed a non-serious event of temperature excursion for opened ipol was administered to patient with no adverse event (poor quality product administered) (latency: same day).  Lab data was not reported.  Action taken was not applicable.  Outcome: Unknown for the event temperature excursion for opened ipol was administered to patient with no adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Sex: U
Vaccine: RAB
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: tested positive for covid; Initial information received on 30-May-2023 regarding an unsolicited valid  non-serious case received from a pharmacist.  This case involves an unknown age and unknown gender patient who experienced tested positive for covid while receiving vaccine Rabies (Hdc) Vaccine [Imovax Rabies].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose 1 of suspect Rabies (Hdc) Vaccine, Powder and solvent for suspension for injection, dose: 0.5 ml (lot number, expiry date: not reported) (strength: unknown) via unknown route in unknown administration site for immunisation.  "Information on the batch number was requested."  On an unknown date the patient tested positive for covid (covid-19) (unknown latency) following the administration of Rabies (Hdc) Vaccine.  It was reported, "Pharmacist is asking about IMOVAX. 2 doses is required. The patient received the first shot and then tested positive for COVID. What is the recommendation now for the 2nd shot? Pharmacist inquiring about the 2nd administration of IMOVAX to a patient who has tested positive for Covid." First time product used : No Still using product : Yes.  Relevant laboratory test results included: SARS-CoV-2 test - On an unknown date: Positive  Action taken with Rabies Vaccine was not applicable.  It was not reported if the patient received a corrective treatment for the event.  At time of reporting, the outcome was Unknown for the event.
Age: 41.0
Sex: M
Vaccine: COVID19, COVID19-2
Symptoms: COVID-19, Condition aggravated, Discomfort, Dysaesthesia, Malaise
Clinical narrative: I have had evolving chronic pain symptoms following a whiplash injury.  Since approximately 2018 I have had increasing symptoms which seem neuropathic in nature, particular dysaesthesia in the frontal scalp (feelings of tightness and vague discomfort).  After each dose of the Moderna vaccine, I experienced a brief (ca. 1 day) exacerbation of these symptoms along with malaise with an onset beginning ~8-12 hours after administration.   I subsequently contracted Covid in January 2023 and experienced a similar but much more severe exacerbation of symptoms lasting several days along with severe malaise and fever (~103F).
Age: 41.0
Sex: M
Vaccine: COVID19, COVID19-2
Symptoms: Neuralgia, Pain, Pyrexia
Clinical narrative: I have had evolving chronic pain symptoms following a whiplash injury.  Since approximately 2018 I have had increasing symptoms which seem neuropathic in nature, particular dysaesthesia in the frontal scalp (feelings of tightness and vague discomfort).  After each dose of the Moderna vaccine, I experienced a brief (ca. 1 day) exacerbation of these symptoms along with malaise with an onset beginning ~8-12 hours after administration.   I subsequently contracted Covid in January 2023 and experienced a similar but much more severe exacerbation of symptoms lasting several days along with severe malaise and fever (~103F).
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Herpes zoster, Vaccination failure
Clinical narrative: Has an outbreak of shingles every month/ suspected vaccination failure; Shingles; This serious case was reported by a consumer via call center representative and described the occurrence of vaccination failure in a 62-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included herpes zoster (Gotten shingles in a small patch on hips in early 20's.).   On an unknown date, the patient received the 2nd dose of Shingrix and the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix and Shingrix, the patient experienced vaccination failure (Verbatim: Has an outbreak of shingles every month/ suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: Shingles). The outcome of the vaccination failure was unknown and the outcome of the shingles was not resolved.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix and Shingrix.     It was unknown if the company considered the vaccination failure and shingles to be related to Shingrix and Shingrix.   Additional Information: GSK Receipt Date: 23-MAY-2023 This case reported by the patient for himself. The reporter reported that he or she got shingles in a small patch on his or her hips since his or her early 20's. The reporter reported that it was happened may be 2 times a year. The reporter reported that someone convinced his or her to get the Shingles vaccine. The reporter reported that he or she get the shingles nearly every month. The reporter reported that her or his life was much worse now. Consumer consents to HCP follow up but has limited details at the time of the call.
Age: 25.0
Sex: F
Vaccine: DTP, TD
Symptoms: Medication error, No adverse event, Wrong product administered
Clinical narrative: inadvertent administration of TENIVAC instead of the intended TDAP vaccine with no reported adverse event; Initial information was received on 30-May-2023 regarding an unsolicited valid non-serious case received from a pharmacist.  This case involves 25 years old female patient who reported that inadvertent administration of tenivac instead of the intended tdap vaccine with no reported adverse event after receiving vaccines DIPHTHERIA, TETANUS and not otherwise specified PERTUSSIS VACCINE and diphtheria-2/tetanus-5 adsorbed toxoids NO PRESERVATIVE ADULT [Tenivac].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On an unknown date, the patient received a unknown dose of suspect diphtheria-2/tetanus-5 adsorbed toxoids NO PRESERVATIVE ADULT lot U7183AA via intramuscular route in the left deltoid (Suspension for injection) (with unknown strength., expiry date) for prophylactic vaccination (Immunization).  On an unknown date, the patient received a unknown dose of suspect DIPHTHERIA, TETANUS and not otherwise specified PERTUSSIS VACCINE produced by unknown manufacturer (lot number, expiry date, strength, formulation not reported) via unknown route in unknown administration site for prophylactic vaccination(immunization).  On an unknown date the patient developed a non-serious event of inadvertent administration of tenivac instead of the intended tdap vaccine with no reported adverse event (wrong product administered) (unknown latency) following the administration of diphtheria-2/tetanus-5 adsorbed toxoids NO PRESERVATIVE ADULT, (unknown latency) following the administration of DIPHTHERIA and TETANUS and not otherwise specified PERTUSSIS VACCINE.  Action taken with DIPHTHERIA and TETANUS TOXOIDS (Tenivac) and DIPHTHERIA, TETANUS and PERTUSSIS (not otherwise specified) VACCINE (DIPHTHERIA, TETANUS and not otherwise specified PERTUSSIS VACCINE) was not applicable.  At time of reporting, the outcome was Unknown for the event inadvertent administration of tenivac instead of the intended tdap vaccine with no reported adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Sex: F
Vaccine: VARZOS
Symptoms: Blister, Herpes zoster, Pruritus, Rash macular, Scab
Clinical narrative: She had 1 shingle blister appear; blister; scab; shingles blister itched, but was not painful; the scab has come off, but the spot is still there and red; shingles blister itched, but was not painful; the scab has come off, but the spot is still there and red; This non-serious case was reported by a consumer via call center representative and described the occurrence of shingles in a 72-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles (had shingles in the past 6-8 years ago).   In FEB-2023, the patient received the 1st dose of Shingrix (left arm). On 04-MAY-2023, between 2 and 4 months after receiving Shingrix, the patient experienced shingles (Verbatim: She had 1 shingle blister appear) and blister (Verbatim: blister). In MAY-2023, the patient experienced pruritus (Verbatim: shingles blister itched, but was not painful; the scab has come off, but the spot is still there and red), red spotty rash (Verbatim: shingles blister itched, but was not painful; the scab has come off, but the spot is still there and red) and scab (Verbatim: scab). The outcome of the shingles and pruritus were resolving and the outcome of the red spotty rash and scab were not resolved and the outcome of the blister was not reported.   It was unknown if the reporter considered the shingles, pruritus, red spotty rash, blister and scab to be related to Shingrix.     It was unknown if the company considered the shingles, pruritus, red spotty rash, blister and scab to be related to Shingrix.   Additional Information: GSK Receipt Date: 26-MAY-2023 The reporter stated that she received her 1st shingrix dose and had 1 shingles blister. She was 90% sure it appeared on 04May2023 after administration of Shingrix in early February. The patient has had shingles in the past 6-8 years ago, and believed it was shingles based on her previous episode (preexisting Shingrix). The shingles was not diagnosed by a physician. The patient reported that the 1 shingles blister itched, but was not painful it was healing, the scab had come off, but the spot was still there and red on 26thMay2023.  The patient also reported that a day prior to receiving her 1st Shingrix dose, on 03rd May2023 she was scheduled for colonoscopy/prep and was sedated (No further information provided about this event). The patient did not have lot and expiry information for her 1st Shingrix dose. The reporter did not consent to follow up with HCP.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, No adverse event
Clinical narrative: No adverse event; Dose 1 and dose 2 are administered in 2021 and 2023 respetively; This spontaneous case was reported by a nurse and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 and dose 2 are administered in 2021 and 2023 respetively) and NO ADVERSE EVENT (No adverse event) in a 70-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No known allergies were reported. It was unknown whether the patient ever been diagnosed with/ tested positive for COVID-19. It was unknown whether patient had Chronic or long-standing health conditions and Acute illnesses at the time of vaccination and up to one month before.  Concomitant products included VITAMIN D3, MULTIVITAMINS [VITAMINS NOS], HYDROCHLOROTHIAZIDE, LISINOPRIL (LISINOPRIL AND HYDROCHLOROTHIAZIDE), ATORVASTATIN and ASPIRIN [ACETYLSALICYLIC ACID] for an unknown indication.   On 23-Oct-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In January 2023, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In January 2023, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 and dose 2 are administered in 2021 and 2023 respetively). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 and dose 2 are administered in 2021 and 2023 respetively) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 and dose 2 are administered in 2021 and 2023 respetively).    It was unknown if any other vaccines were given in the 4 weeks prior to COVID-19 vaccine. No treatment medications were reported.   This case was linked to MOD-2023-723962 (Patient Link).
Age: 23.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse event; Pharmacist states that they had 6 patients dosed with the bivalent vaccine which were administered one and two days beyond the BUD.; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Pharmacist states that they had 6 patients dosed with the bivalent vaccine which were administered one and two days beyond the BUD.) and NO ADVERSE EVENT (No adverse event) in a 23-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7173B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 25-May-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 25-May-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (Pharmacist states that they had 6 patients dosed with the bivalent vaccine which were administered one and two days beyond the BUD.). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Pharmacist states that they had 6 patients dosed with the bivalent vaccine which were administered one and two days beyond the BUD.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Pharmacist states that they had 6 patients dosed with the bivalent vaccine which were administered one and two days beyond the BUD.).    The case was regarding Patient number 4 out of 6 patients.  No concomitant medications were reported.  Pharmacist stated that they had 6 patients dosed with the bivalent vaccine which were administered one and two days beyond the BUD. The lot number of the vaccine is AS7173B, the date it was pulled out of the freezer was 24-Apr-2023.  Treatment information was not provided.   This case was linked to US-MODERNATX, INC.-MOD-2023-726797 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 30-May-2023: Live follow-up appended with no new information. On 30-May-2023: Live Significant follow-up appended: Patient details updated and Narrative updated.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-726797:Patient 1
Age: 78.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse event; patient received vaccine beyond its use by date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (patient received vaccine beyond its use by date) and NO ADVERSE EVENT (No adverse event) in a 78-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 011H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 25-May-2023, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 25-May-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (patient received vaccine beyond its use by date). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (patient received vaccine beyond its use by date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (patient received vaccine beyond its use by date).    It was reported that the patient did not receive any other vaccines in the 4 weeks prior to COVID-19 vaccine. No concomitant medication was reported. No treatment medication was reported.
Age: 52.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site erythema, Injection site pain, Injection site swelling
Clinical narrative: Site: Pain at Injection Site-Mild, Site: Redness at Injection Site-Mild, Site: Swelling at Injection Site-Mild, Additional Details: pt reports soreness and redness and swelling at injection site; inquiring if normal; characterzied as mild
Age: 66.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site erythema, Injection site pain, Injection site pruritus, Injection site warmth, Pyrexia
Clinical narrative: Site: Bruising at Injection Site-Mild, Site: Itching at Injection Site-Mild, Site: Pain at Injection Site-Mild, Site: Redness at Injection Site-Mild, Site: Swelling at Injection Site-Mild, Systemic: Fever-Mild, Additional Details: Patient presented to pharmacy with injection site reaction, left arm was red, warm and tender, patient stated felt slight itch. Provided antihistamine and steroid cream to alleviate symptoms, pt stated slight fever that resolved quickly and arm was improving. Advised to notify if condition worsens and to contact provider if necessary. Patient to be counseled during second dose of Shingrix.
Age: 21.0
Sex: F
Vaccine: HEPA
Symptoms: Dizziness, Fall, Headache, Joint injury, Mydriasis
Clinical narrative: Systemic: Dizziness / Lightheadness-Mild, Systemic: Fainting / Unresponsive-Medium, Systemic: scraped knee when she fell-did not bleed-Mild, Systemic: Headache-Medium, Systemic: Nausea-Mild, Additional Details: water given by parents for nausea. Laid down on bench parents reported dilated pupils-advised to avoid activity today-was going to the zoo with friends. Stayed 1hr until she felt she can leave.
Age: 21.0
Sex: F
Vaccine: HEPA
Symptoms: Nausea, Syncope, Unresponsive to stimuli
Clinical narrative: Systemic: Dizziness / Lightheadness-Mild, Systemic: Fainting / Unresponsive-Medium, Systemic: scraped knee when she fell-did not bleed-Mild, Systemic: Headache-Medium, Systemic: Nausea-Mild, Additional Details: water given by parents for nausea. Laid down on bench parents reported dilated pupils-advised to avoid activity today-was going to the zoo with friends. Stayed 1hr until she felt she can leave.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Obstructive sleep apnoea syndrome
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE OBSTRUCTIVE SLEEP APNEA
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Neuropathy peripheral, Pericarditis
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE PERIPHERAL NEUROPATHY ACUTE PERICARDITIS, UNSPECIFIED
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Chronic inflammatory demyelinating polyradiculoneuropathy, Guillain-Barre syndrome, Nausea, Suspected COVID-19, Vomiting
Clinical narrative: CIDP (CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY); GUILLAIN-BARRE; SUSPECTED COVID-19 INFECTION; NAUSEA; VOMITING; This spontaneous report received from a consumer concerned a 51 year old male. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included: The patient had no illness at the time of vaccination. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, 1 total administered on 09-MAR-2021 to left deltoid for covid-19 prophylaxis. The batch number was not reported and has been requested. Age at time of vaccination 51 years old. No concomitant medications were reported.  On an unspecified date in 2021 after the injection, the patient experienced nausea and vomiting. On an unspecified date in 2021, shortly after receiving vaccine, the patient caught COVID (suspected covid-19 infection). On 14-APR-2023, patient saw neurologist who said that the COVID vaccine might had triggered patient's onset of CIDP (Chronic inflammatory demyelinating polyradiculoneuropathy). On an unspecified date, the patient had Guillain-Barre. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the nausea, vomiting, suspected covid-19 infection, CIDP (Chronic inflammatory demyelinating polyradiculoneuropathy) and Guillain-Barre was not reported. This report was serious (Other Medically Important Condition).; Sender's Comments: V0:20230569029- Guillain-Barre. The event has an unknown/unclear temporal relationship, and is labeled. There is no information on any other factors potentially associated with the event. Therefore, this event is considered consistent with vaccine administration. 20230569029-CIDP (Chronic inflammatory demyelinating polyradiculoneuropathy). The event has an unknown/unclear temporal relationship, is unlabeled, and is scientifically plausible. There is no information on any other factors potentially associated with the event. Therefore, the Causality is considered indeterminate. The company causality is considered unassessable.
Age: 41.0
Sex: M
Vaccine: COVID19
Symptoms: Obstructive sleep apnoea syndrome
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE OBSTRUCTIVE SLEEP APNEA
Age: 24.0
Sex: M
Vaccine: COVID19
Symptoms: Rash, Urticaria
Clinical narrative: recurrent daily urticaric rash controlled with antihistamine BID dosing.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, Chronic respiratory failure, Neuropathy peripheral, Obstructive sleep apnoea syndrome, Respiratory failure
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE SLEEP APNEA ADULT OBSTRUCTIVE SLEEP APNEA PERIPHERAL NEUROPATHY ACUTE RESPIRATORY FAILURE ACUTE HYPOXEMIC RESPIRATORY FAILURE CHRONIC HYPOXEMIC RESPIRATORY FAILURE CHRONIC HYPERCAPNIC RESPIRATORY FAILURE ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE ACUTE ON CHRONIC HYPERCAPNIC RESPIRATORY FAILURE RESPIRATORY FAILURE, UNSPECIFIED ACUITY 4/8/2022,  5/26/2022,  6/13/2022,  7/7/2022,  7/31/2022,  9/8/2022,  10/11/2022,  10/25/2022,  2/5/2022,   11/12/2022,  12/21/2022,  2/1/2023,  3/12/2023,  3/2/2023  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Sleep apnoea syndrome, Symptom recurrence
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE SLEEP APNEA ADULT OBSTRUCTIVE SLEEP APNEA PERIPHERAL NEUROPATHY ACUTE RESPIRATORY FAILURE ACUTE HYPOXEMIC RESPIRATORY FAILURE CHRONIC HYPOXEMIC RESPIRATORY FAILURE CHRONIC HYPERCAPNIC RESPIRATORY FAILURE ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE ACUTE ON CHRONIC HYPERCAPNIC RESPIRATORY FAILURE RESPIRATORY FAILURE, UNSPECIFIED ACUITY 4/8/2022,  5/26/2022,  6/13/2022,  7/7/2022,  7/31/2022,  9/8/2022,  10/11/2022,  10/25/2022,  2/5/2022,   11/12/2022,  12/21/2022,  2/1/2023,  3/12/2023,  3/2/2023  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Age: 30.0
Sex: F
Vaccine: COVID19-2
Symptoms: Abortion spontaneous, Exposure during pregnancy
Clinical narrative: Event- miscarriage History- 5 weeks pregnant, previous miscarriage in May 2022
Age: 85.0
Sex: F
Vaccine: COVID19
Symptoms: Deep vein thrombosis
Clinical narrative: ACUTE DVT OF LEFT LEG, UNSPECIFIED VEIN
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoxia
Clinical narrative: HYPOXIA
Age: 67.0
Sex: M
Vaccine: VARZOS
Symptoms: Injection site pain, Nausea
Clinical narrative: Nausea, sore arm at injection site.
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Myocarditis
Clinical narrative: Patient filled out Post-Covid Vaccine survey on 5/23/23 for his vaccination on 5/18/2021 (2nd dose Moderna vaccination). He reported Myocarditis following vaccination.   I do not have any medical records to show this. Please contact the patient for further follow up.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Neuropathy peripheral
Clinical narrative: PERIPHERAL NEUROPATHY
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Obstructive sleep apnoea syndrome
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE OBSTRUCTIVE SLEEP APNEA
Age: 57.0
Sex: M
Vaccine: COVID19
Symptoms: Acute myocardial infarction, Acute respiratory failure
Clinical narrative: ACUTE NON ST ELEVATION MI ACUTE RESPIRATORY FAILURE
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Encephalopathy
Clinical narrative: cute encephalopathy
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Deep vein thrombosis
Clinical narrative: ACUTE DVT, UNSPECIFIED VEIN
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Pulmonary embolism
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE ACUTE PULMONARY EMBOLISM
Age: 51.0
Sex: F
Vaccine: HEPAB, VARZOS
Symptoms: Abdominal pain, Headache, Insomnia, Myalgia, Nausea
Clinical narrative: Insomnia, then nausea, morning headache and muscle pain. Rt side sharp abdominal pain
Age: 57.0
Sex: M
Vaccine: COVID19
Symptoms: Acute myocardial infarction, Myocardial infarction
Clinical narrative: ACUTE ST ELEVATION MI, INFEROLATERAL WALL
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Neuropathy peripheral
Clinical narrative: PERIPHERAL NEUROPATHY
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Hypotension
Clinical narrative: HYPOTENSION
Age: 66.0
Sex: F
Vaccine: COVID19-2
Symptoms: Asthenia, Blood electrolytes decreased, Blood potassium decreased, COVID-19, Loss of consciousness
Clinical narrative: I did not have an adverse reaction to the Pfizer Bivalent vaccine.  I woke up on 12/17/2022 and was walking down the hallway towards my kitchen and passed out three times. I went to the emergency room for observation and admitted for three days to the COVID-19 ward. I tested positive for COVID-19 on 12/17/2022. My electrolytes and potassium were very low which is why I passed out and at danger for cardiac arrest.  It took about a month to gain my strength. As of today, I feel better with no lingering symptoms.
Age: 66.0
Sex: F
Vaccine: COVID19-2
Symptoms: SARS-CoV-2 test positive
Clinical narrative: I did not have an adverse reaction to the Pfizer Bivalent vaccine.  I woke up on 12/17/2022 and was walking down the hallway towards my kitchen and passed out three times. I went to the emergency room for observation and admitted for three days to the COVID-19 ward. I tested positive for COVID-19 on 12/17/2022. My electrolytes and potassium were very low which is why I passed out and at danger for cardiac arrest.  It took about a month to gain my strength. As of today, I feel better with no lingering symptoms.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Deep vein thrombosis, Pulmonary embolism
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE SADDLE PULMONARY EMBOLISM ACUTE DVT OF RIGHT LEG, UNSPECIFIED VEIN
Age: 13.0
Sex: F
Vaccine: HPV9
Symptoms: Dizziness
Clinical narrative: Client received HPV 2 dose.  No history of syncope with vaccines or any medical treatments.  Pt received 3 vaccines last year 06/03/2022, HPV, Tdap and MCV4 without syncope episode.  Father and client escorted to cashier window.  Patient became dizzy and patient assisted to a chair.  Cold compresses applied to neck, legs elevated, and patient monitored.  Pt alert and oriented after a minute, no c/o dizziness, pt monitored for 30 minutes after episode.  Client given water and a snack.  Client left with father.
Age: 42.0
Sex: M
Vaccine: COVID19-2
Symptoms: Chronic spontaneous urticaria
Clinical narrative: I was diagnosed with Chronic Spontaneous Urticaria, also known as hives. They started on April 11, 2023. They've been ongoing. They appear on my chest, neck, and hands. They vary in size and shape. They last several hours each day.
Age: 73.0
Sex: M
Vaccine: COVID19
Symptoms: Coagulopathy, Symptom recurrence
Clinical narrative: COAGULOPATHY, UNSPECIFIED TYPE 2/16/2023 -- RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: Neuropathy peripheral
Clinical narrative: NEUROPATHY
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Ear infection, Headache, Lymphadenopathy, SARS-CoV-2 test negative, Sinusitis
Clinical narrative: I had a sinus and ear infection, severe headache, swollen lymph glands. I took a home COVID-19 test that came back negative, I called my doctor but was unable to get in as they were very busy. I went to a local Urgent Care. Upon examination I was given Z-pack and Prednisone for the sinus and ear infection. It did take a couple of days for the medication to start working.
Age: 50.0
Sex: M
Vaccine: TDAP
Symptoms: Blood test, Joint swelling, Pain, Pain in extremity, Peripheral swelling
Clinical narrative: Pain from left arm down left side of body about 1 hour after had tdap on 5.26. Did also have blood drawn from same arm here that day. Was initially swollen on arm and left knee swollen- within an hour. States was not experiencing any of these symptoms at the time of the visit. Never experienced this with any other vaccine.  left knee swelling persists.
Age: 50.0
Sex: M
Vaccine: TDAP
Symptoms: X-ray limb
Clinical narrative: Pain from left arm down left side of body about 1 hour after had tdap on 5.26. Did also have blood drawn from same arm here that day. Was initially swollen on arm and left knee swollen- within an hour. States was not experiencing any of these symptoms at the time of the visit. Never experienced this with any other vaccine.  left knee swelling persists.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, Symptom recurrence
Clinical narrative: ACUTE HYPOXEMIC RESPIRATORY FAILURE 9/16/2022  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Age: 67.0
Sex: F
Vaccine: VARZOS
Symptoms: Echocardiogram normal, Electrocardiogram ambulatory normal, Electrocardiogram normal, Pain, Palpitations
Clinical narrative: The following day I had fever and achiness which I expected and started palpitations which have not subsided. I have seen a cardiologist and have had multiple tests done which were normal.
Age: 67.0
Sex: F
Vaccine: VARZOS
Symptoms: Pyrexia
Clinical narrative: The following day I had fever and achiness which I expected and started palpitations which have not subsided. I have seen a cardiologist and have had multiple tests done which were normal.
Age: 7.0
Sex: U
Vaccine: DTAP, HEP, HEPA, IPV, MMR, VARCEL
Symptoms: Unevaluable event
Clinical narrative: NONE
Age: 87.0
Sex: F
Vaccine: COVID19
Symptoms: Hypertension, Partial seizures
Clinical narrative: G40.89 FOCAL MOTOR SEIZURE 1/16/2023 HTN (HYPERTENSION)
Age: 87.0
Sex: M
Vaccine: COVID19
Symptoms: Hypotension, Lacunar stroke
Clinical narrative: ACUTE LACUNAR STROKE, UNSPECIFIED TYPE AND ARTERY HYPOTENSION
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: Acute kidney injury, Acute respiratory failure, Chronic hepatitis B
Clinical narrative: J96.20 ACUTE ON CHRONIC RESPIRATORY FAILURE 2/24/2023 ACUTE ON CHRONIC RESPIRATORY FAILURE J96.20 ACUTE ON CHRONIC RESPIRATORY FAILURE 2/24/2023 ACUTE RENAL FAILURE, UNSPECIFIED J96.20 ACUTE ON CHRONIC RESPIRATORY FAILURE 2/24/2023 CHRONIC HEPATITIS B
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Acute myocardial infarction
Clinical narrative: ACUTE NON ST ELEVATION MI
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Coronary artery disease, Hypotension
Clinical narrative: I95.9 HYPOTENSION 11/30/2022 CAD (CORONARY ARTERY DISEASE) WO ANGINA
Age: 46.0
Sex: M
Vaccine: COVID19
Symptoms: Cerebrovascular accident
Clinical narrative: ACUTE STROKE, UNSPECIFIED TYPE AND ARTERY
Age: 0.75
Sex: F
Vaccine: VARCEL
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: Varivax administerd to 9 month old
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE ACUTE RESPIRATORY FAILURE
Age: 3.0
Sex: F
Vaccine: FLU4
Symptoms: Injection site erythema, Injection site mass
Clinical narrative: Patient presented to clinic with large lump and redness around injection site.  Patient was prescribed Amoxicillin 400mg/5mL oral suspension.  Patient returned for evaluation and symptoms improved.
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Hypoxia, Symptom recurrence
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE HYPOXIA 4/1/2022 -- RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Abnormal menstrual clots, Aphasia, Asthenia, Blood iron, Blood thyroid stimulating hormone
Clinical narrative: Initially numbness and tingling in bilateral lower extremities, weakness, then Lhermitte's sign, then complete numbness in left side of body, intense brain fog, trouble forming sentences, heat sensitivity. Had a series of MRI's done and lumbar puncture. Diagnosed with Multiple Sclerosis on July 16, 2021. Had no previous signs or symptoms. Also has irregular, prolonged, heavy menstrual cycle with immense clotting.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Brain fog, Full blood count, Heavy menstrual bleeding, Hypoaesthesia, Laboratory test
Clinical narrative: Initially numbness and tingling in bilateral lower extremities, weakness, then Lhermitte's sign, then complete numbness in left side of body, intense brain fog, trouble forming sentences, heat sensitivity. Had a series of MRI's done and lumbar puncture. Diagnosed with Multiple Sclerosis on July 16, 2021. Had no previous signs or symptoms. Also has irregular, prolonged, heavy menstrual cycle with immense clotting.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Lhermitte's sign, Lipids, Lumbar puncture, Magnetic resonance imaging head, Magnetic resonance imaging spinal
Clinical narrative: Initially numbness and tingling in bilateral lower extremities, weakness, then Lhermitte's sign, then complete numbness in left side of body, intense brain fog, trouble forming sentences, heat sensitivity. Had a series of MRI's done and lumbar puncture. Diagnosed with Multiple Sclerosis on July 16, 2021. Had no previous signs or symptoms. Also has irregular, prolonged, heavy menstrual cycle with immense clotting.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Menstruation irregular, Metabolic function test, Multiple sclerosis, Oligomenorrhoea, Paraesthesia
Clinical narrative: Initially numbness and tingling in bilateral lower extremities, weakness, then Lhermitte's sign, then complete numbness in left side of body, intense brain fog, trouble forming sentences, heat sensitivity. Had a series of MRI's done and lumbar puncture. Diagnosed with Multiple Sclerosis on July 16, 2021. Had no previous signs or symptoms. Also has irregular, prolonged, heavy menstrual cycle with immense clotting.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Scan with contrast, Spinal X-ray, Temperature intolerance, Thyroxine, Vitamin B12
Clinical narrative: Initially numbness and tingling in bilateral lower extremities, weakness, then Lhermitte's sign, then complete numbness in left side of body, intense brain fog, trouble forming sentences, heat sensitivity. Had a series of MRI's done and lumbar puncture. Diagnosed with Multiple Sclerosis on July 16, 2021. Had no previous signs or symptoms. Also has irregular, prolonged, heavy menstrual cycle with immense clotting.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Vitamin D
Clinical narrative: Initially numbness and tingling in bilateral lower extremities, weakness, then Lhermitte's sign, then complete numbness in left side of body, intense brain fog, trouble forming sentences, heat sensitivity. Had a series of MRI's done and lumbar puncture. Diagnosed with Multiple Sclerosis on July 16, 2021. Had no previous signs or symptoms. Also has irregular, prolonged, heavy menstrual cycle with immense clotting.
Age: 36.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: Vaccine was expired.  The Pfizer vaccine was delivered on 12/8  and is viable in refrigeration for 10 weeks from that date is 2/16/23. The vaccine was administered on 3/21/23. So about 4 weeks expired.
Age: 94.0
Sex: M
Vaccine: COVID19
Symptoms: Dementia Alzheimer's type, Hydronephrosis, Hypotension, Organ failure, Sepsis
Clinical narrative: I95.9 HYPOTENSION 1/27/2023 HYDRONEPHROSIS I95.9 HYPOTENSION 1/27/2023 SEVERE SEPSIS W ACUTE ORGAN DYSFUNCTION I95.9 HYPOTENSION 1/27/2023 ALZHEIMERS DISEASE
Age: 35.0
Sex: M
Vaccine: COVID19
Symptoms: Acute myocardial infarction, Symptom recurrence
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE ACUTE NON ST ELEVATION MI 1/25/2022  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoxia, Pulmonary embolism
Clinical narrative: ACUTE PULMONARY EMBOLISM HYPOXIA
Age: 85.0
Sex: F
Vaccine: COVID19
Symptoms: Ischaemic stroke
Clinical narrative: ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: Embolic stroke, Epilepsy, Partial seizures, Transient ischaemic attack
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE PARTIAL EPILEPSY EPILEPSY, UNSPECIFIED TRANSIENT CEREBRAL ISCHEMIA ACUTE STROKE DUE TO EMBOLISM OF UNSPECIFIED ARTERY
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Haematemesis, Hypotension, Neuropathy peripheral, Obstructive sleep apnoea syndrome, Pancreatic carcinoma
Clinical narrative: Pfizer vaccine was administered outside of Facility - reported by patient- ? NO LOT NUMBER WERE SUPPLIED ----------------------------------------------------------------------------------------------------------------------------- G47.33 ADULT OBSTRUCTIVE SLEEP APNEA, MILD 11/15/2022 PANCREATIC MASS G62.0 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY, INIT 12/14/2022 PANCREATIC MASS I95.9 HYPOTENSION 10/10/2022 PANCREATIC MASS R57.9 SHOCK, UNSPECIFIED 1/13/2023 PANCREATIC MASS G47.33 ADULT OBSTRUCTIVE SLEEP APNEA, MILD 11/15/2022 PANCREATIC CANCER, UNSPECIFIED SITE G62.0 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY, INIT 12/14/2022 PANCREATIC CANCER, UNSPECIFIED SITE I95.9 HYPOTENSION 10/10/2022 PANCREATIC CANCER, UNSPECIFIED SITE R57.9 SHOCK, UNSPECIFIED 1/13/2023 PANCREATIC CANCER, UNSPECIFIED SITE G47.33 ADULT OBSTRUCTIVE SLEEP APNEA, MILD 11/15/2022 HEMATEMESIS G62.0 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY, INIT 12/14/2022 HEMATEMESIS I95.9 HYPOTENSION 10/10/2022 HEMATEMESIS R57.9 SHOCK, UNSPECIFIED 1/13/2023 HEMATEMESIS
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Pancreatic mass, Shock
Clinical narrative: Pfizer vaccine was administered outside of Facility - reported by patient- ? NO LOT NUMBER WERE SUPPLIED ----------------------------------------------------------------------------------------------------------------------------- G47.33 ADULT OBSTRUCTIVE SLEEP APNEA, MILD 11/15/2022 PANCREATIC MASS G62.0 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY, INIT 12/14/2022 PANCREATIC MASS I95.9 HYPOTENSION 10/10/2022 PANCREATIC MASS R57.9 SHOCK, UNSPECIFIED 1/13/2023 PANCREATIC MASS G47.33 ADULT OBSTRUCTIVE SLEEP APNEA, MILD 11/15/2022 PANCREATIC CANCER, UNSPECIFIED SITE G62.0 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY, INIT 12/14/2022 PANCREATIC CANCER, UNSPECIFIED SITE I95.9 HYPOTENSION 10/10/2022 PANCREATIC CANCER, UNSPECIFIED SITE R57.9 SHOCK, UNSPECIFIED 1/13/2023 PANCREATIC CANCER, UNSPECIFIED SITE G47.33 ADULT OBSTRUCTIVE SLEEP APNEA, MILD 11/15/2022 HEMATEMESIS G62.0 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY, INIT 12/14/2022 HEMATEMESIS I95.9 HYPOTENSION 10/10/2022 HEMATEMESIS R57.9 SHOCK, UNSPECIFIED 1/13/2023 HEMATEMESIS
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Angina pectoris
Clinical narrative: ANGINA, UNSPECIFIED
Age: 67.0
Sex: M
Vaccine: COVID19-2
Symptoms: COVID-19, Cough, Exposure to SARS-CoV-2, Fatigue, Pain in extremity
Clinical narrative: I had a very mild soreness in my arm after receiving the Moderna vaccine for Dose 6. I was exposed to COVID-19 while on vacation. I tested positive for COVID-19 on 05/25/2023. I had a terrible cough and a runny nose. I went to an urgent care center and got a prescription for molnupiravir. The medication worked immediately.  I did have diarrhea on day three of taking the medication. As of today, I still feel fatigue and a runny nose.
Age: 67.0
Sex: M
Vaccine: COVID19-2
Symptoms: Rhinorrhoea, SARS-CoV-2 test positive
Clinical narrative: I had a very mild soreness in my arm after receiving the Moderna vaccine for Dose 6. I was exposed to COVID-19 while on vacation. I tested positive for COVID-19 on 05/25/2023. I had a terrible cough and a runny nose. I went to an urgent care center and got a prescription for molnupiravir. The medication worked immediately.  I did have diarrhea on day three of taking the medication. As of today, I still feel fatigue and a runny nose.
Age: 80.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: Vaccine was pulled from Freezer on 5/19/23, giving an expiration of 6/18/23, since it is good thawed for 30 days.  Actual expiration date was 5/27/23.  This was noted on the box in the freezer but not on the box in the fridge.     No adverse reactions.  Moderna is doing a Lot assessment to determine the activity level of the vaccine.  The report will done in 3-5 business days and then we will know whether we have to revaccinate or not.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Hypersensitivity
Clinical narrative: ALLERGIC REACTION, INIT
Age: 90.0
Sex: M
Vaccine: COVID19
Symptoms: Anaemia, Hyponatraemia, Hypotension
Clinical narrative: I95.9 HYPOTENSION 9/1/2022 ANEMIA I95.9 HYPOTENSION 9/1/2022 HYPONATREMIA
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, Respiratory failure
Clinical narrative: ACUTE RESPIRATORY FAILURE ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE
Age: 0.5
Sex: U
Vaccine: DTAPHEPBIP
Symptoms: No adverse event
Clinical narrative: Mother stated no reactions have occurred
Age: 41.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: VACCINE ADMINISTERED OUTSIDE OF THE SUGESTED VACCINATION DATE OF USE
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Transient ischaemic attack
Clinical narrative: TRANSIENT CEREBRAL ISCHEMIA
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Hospitalized with covid; fully vaccinated with 2 boosters
Age: 63.0
Sex: F
Vaccine: COVID19-2
Symptoms: Ageusia, Anosmia, Chills, Dysphagia, Headache
Clinical narrative: I experienced chills, fever, trouble swallowing, loss of taste/smell, mucus, runny nose and headache.
Age: 63.0
Sex: F
Vaccine: COVID19-2
Symptoms: Pyrexia, Rhinorrhoea, Secretion discharge
Clinical narrative: I experienced chills, fever, trouble swallowing, loss of taste/smell, mucus, runny nose and headache.
Age: 57.0
Sex: M
Vaccine: COVID19
Symptoms: Acute myocardial infarction
Clinical narrative: ACUTE NON ST ELEVATION MI